Verve Therapeutics

Subsidiary of Eli Lilly (LLY)

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
PCSK9 gene (hepatocyte genomic DNA)Gene therapy / editing
Atherosclerotic Cardiovascular Disease
Phase 1
ANGPTL3 gene (hepatocyte genomic DNA)Gene therapy / editing
Atherosclerotic Cardiovascular DiseaseCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
August 2028 (1)
VERVE-102Phase 2Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Est. primary completion 2028-08 · NCT07839936 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1—$54M$101M+ $401M short-term inv.$31Mreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q3—$50M$163M+ $381M short-term inv.$50Mreport ↗
2024-Q2—$51M$146M+ $434M short-term inv.$50Mreport ↗
2024-Q1—$48M$149M+ $462M short-term inv.$49Mreport ↗
2023-Q3—$44M$83M+ $407M short-term inv.$46Mreport ↗
2023-Q2—$47M$75M+ $392M short-term inv.$54Mreport ↗
2023-Q1—$47M$89M+ $425M short-term inv.$52Mreport ↗
2022-Q3—$35M$282M+ $274M short-term inv.$45Mreport ↗
2022-Q2—$33M$78M+ $221M short-term inv.$41Mreport ↗
2022-Q1—$24M$97M+ $232M short-term inv.$30Mreport ↗
2021-Q3—$18M$153M+ $241M short-term inv.$23Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$204M$177M+ $352M short-term inv.$50Mreport ↗

Verve Therapeutics reported R&D spend of $204.35M, up 10.5% YoY, cash and equivalents of $177.33M, and a net loss of $198.71M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY—$185M$211M+ $418M short-term inv.$50Mreport ↗
2022-FY—$130M$120M+ $439M short-term inv.$39Mreport ↗
2021-FY—$68M$70M+ $296M short-term inv.$30Mreport ↗